Literature DB >> 2174732

Role of estrogen-induced insulin-like growth factors in the proliferation of human breast cancer cells.

B van der Burg1, L Isbrücker, A J van Selm-Miltenburg, S W de Laat, E J van Zoelen.   

Abstract

Insulin-like growth factor I (IGF-I) is the most potent growth factor for estrogen (E2)-dependent breast cancer cell lines. It has been reported that such cell lines produce an immunoreactive IGF-I-related protein in an E2-dependent fashion, while autonomously growing cell lines constitutively produce these factors, indicating that they might be involved in autocrine growth stimulation of breast cancer cells. We have studied the role of IGFs in autocrine growth stimulation of the E2-dependent breast cancer cell line MCF7 by using IGF-binding proteins (BPs) that were able to neutralize completely the mitogenic effect of IGF-I on this cell line. These BPs, however, did not have any inhibitory effect on E2-induced mitogenesis, suggesting that secretion of autocrine IGFs is not involved in growth stimulation by E2. To exclude the possibility that variants of IGF are produced by the cells that are not recognized by the BPs, we also studied the production of biologically active IGF using the same MCF7 cell line in a sensitive bioassay in which the various forms of IGF and insulin can be detected. Although the conditioned medium (CM) of human fibroblasts used as a control showed IGF-like activity in this assay, no such activity was detected in CM of both untreated and E2-stimulated MCF7 cells, while the CM of the E2-independent cell lines BT20 and Hs578T had only slight mitogenic activity or was even growth inhibitory, respectively. These data show that no significant secretion of biologically active IGFs by human breast cancer cells could be detected and do not support a possible autocrine function of IGFs in the proliferation of such cells. Because E2-dependent cells strongly react to externally added IGF-like factors produced by human fibroblasts, a role for IGFs in paracrine regulation of proliferation is suggested.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174732

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  The insulin-like growth factor binding proteins (IGFBPs) in human breast cancer.

Authors:  J A Figueroa; D Yee
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 2.  Interference of the IGF system as a strategy to inhibit breast cancer growth.

Authors:  C L Arteaga
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

3.  Growth factor involvement in the multihormonal regulation of MCF-7 breast cancer cell growth in soft agar.

Authors:  A Manni; C Wright; H Buck
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

4.  Establishment and characteristics of two new human mammary carcinoma lines in nude mice with special reference to the estradiol receptor status and the importance of stroma for in vivo and in vitro growth.

Authors:  H Naundorf; I Fichtner; B Elbe; G J Saul; W Haensch; W Zschiesche; S Reinecke
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

5.  Fibroblast stimulation of breast cancer cell growth in a serum-free system.

Authors:  M C Ryan; D J Orr; K Horgan
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

6.  17beta-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response.

Authors:  E C Chinje; K J Williams; B A Telfer; P J Wood; A J van der Kogel; I J Stratford
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

7.  Proliferative behaviour of an oestrogen sensitive rat mammary tumour: evidence for a paracrine interaction between tumour and stroma.

Authors:  M G Ormerod; J C Titley; T A Smith; A L Tombs; S Eccles
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

8.  Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines.

Authors:  R E Favoni; A de Cupis; S Bruno; D Yee; A Ferrera; P Pirani; A Costa; A Decensi
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

9.  17beta-Estradiol responsiveness of MCF-7 laboratory strains is dependent on an autocrine signal activating the IGF type I receptor.

Authors:  Irene HL Hamelers; Richard FMA Van Schaik; John S Sussenbach; Paul H Steenbergh
Journal:  Cancer Cell Int       Date:  2003-07-11       Impact factor: 5.722

10.  Identification of Insulin-Like Growth Factor-I Receptor (IGF-IR) Gene Promoter-Binding Proteins in Estrogen Receptor (ER)-Positive and ER-Depleted Breast Cancer Cells.

Authors:  Rive Sarfstein; Antonino Belfiore; Haim Werner
Journal:  Cancers (Basel)       Date:  2010-03-25       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.